The Role of Opioid Adherence Profiles in Cancer Pain Self-Management and Outcomes

阿片类药物依从性在癌痛自我管理和结果中的作用

• 批准号: 10338125
• 负责人: Salimah H. Meghani
• 金额: $ 52.98万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-04-25 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10338125
• 关键词: Accident and Emergency department; Address; Adherence; African American population; Age; American; Analgesics; Area; Attention; Belief; Breakthrough Pain; Cancer Pain Management; Cancer Patient; Cancer Science; Caring; Clinical; Complementary and alternative medicine; Constipation; Data; Dose; Drug Prescriptions; Event; Exclusion Criteria; Flare; Health Services; Healthcare; Hospitalization; Human; Individual; Intervention; Knowledge; Longitudinal Studies; Love; Malignant Neoplasms; Monitor; National Institute of Nursing Research; Oncology; Opioid; Opioid Analgesics; Outcome; Outpatients; Pain; Pain Research; Pain management; Patient Outcomes Assessments; Patient Self-Report; Patients; Pattern; Persons; Pharmaceutical Preparations; Policies; Prospective cohort study; Public Health; Quality of life; Race; Reporting; Research; Role; Schedule; Self Management; Services; Severities; Side; Symptoms; System; Testing; Time; United States National Institutes of Health; Woman; addiction; base; cancer diagnosis; cancer pain; cancer therapy; chronic pain; clinical predictors; cost; daily pain; design; disparity reduction; experience; health care service utilization; health disparity; health management; health related quality of life; improved; knowledge translation; non-opioid analgesic; opioid misuse; opioid therapy; opioid use; pain self-management; prescription opioid; racial disparity; recruit; sex; side effect; sleep health; sociodemographics; socioeconomics; systematic review; therapy development; time use

ABSTRACT/ PROJECT SUMMARY Pain is one of the top symptoms producing the greatest negative impact on cancer patients' quality of life. Unfortunately, one in three cancer patients will experience moderate to severe pain due to consequences of cancer, its treatments or both. For one in three, pain will persist after completion of active cancer treatments. With 15.5 million Americans living with cancer, this is a substantial public health matter. While many complementary and alternative medicine approaches exist, their clinical use for cancer pain remains seriously hampered by lack of robust evidence, short-term relief, and excessive out-of-pocket costs. In turn, opioid pain medications are prescribed to cancer patients – who notably, also remain excluded from most state and policy initiatives on opioids. Long-term (>3 months ) opioid therapy is also prevalent among cancer outpatients when compared to age-sex matched controls. Despite this, cancer patients have been almost invariably excluded from T he recent Health management” studies investigating the outcomes of long-term opioid therapy and use. and Human Services Pain Management Inter-Agency Taskforce has identified “self- as one of the best practices in improving chronic pain. However,interventions cannot be designed due to serious gaps in our current understanding of cancer outpatients' pain self-management and especially their opioid self-management. Recent systematic reviews demonstrate that most cancer pain interventions (based on knowledge translation and conducted predominantly or exclusively with White patients) improve knowledge, but largely do not improve outcomes that matter to patients such as daily pain, function, or quality of life. This underscores a need to continue in search of other targets for intervention development. This 6-month prospective cohort study will generate new knowledge about longitudinal pain, opioid self- management trajectories, and associated outcomes among cancer outpatients in the context of daily pain, pain flares, key clinical moderators and covariates. A total of 400 cancer outpatients (50% African Americans; 50% women) who are prescribed long-acting (LA) opioids will be recruited from three urban oncology centers. Longitudinal opioid self-management patterns will be captured in real-time using medication event monitoring system (MEMS®). Daily background pain, pain flares, and use of “as-needed” opioids will be collected using the self-report tracker (SRT®). Patient-reported outcomes (PRO) to be assessed are changes in pain levels, function, sleep, and health-related quality of life. Health services outcomes include unplanned hospitalizations and emergency department use (healthcare utilization). This study will supply rigorous data, comprehensive set of sociodemographic and clinical covariates, and key moderators upon which further research for pain-self management best practices can be based, including targets to ameliorate racial disparities. Overall, this research can have a sustained impact on the science of cancer pain management.

摘要/项目摘要 疼痛是对癌症患者的生活质量产生最大负面影响的首要症状之一。 不幸的是，三分之一的癌症患者会因以下后果而经历中度至重度疼痛： 三分之一的人在完成积极的癌症治疗后仍会持续疼痛。 有 1550 万美国人患有癌症，这是一个重大的公共卫生问题。 补充和替代医学方法是存在的，但它们在临床上用于治疗癌症疼痛仍然受到重视 由于缺乏有力的证据、短期缓解以及过多的自付费用而受到阻碍。 药物是给癌症患者开的——值得注意的是，他们仍然被排除在大多数国家和政策之外 长期（>3 月 ）阿片类药物治疗在癌症门诊患者中也很普遍 尽管如此，癌症患者几乎总是与年龄性别匹配的对照组相比。 排除 从 时间 他最近的健康状况 “管理” 研究调查长期阿片类药物治疗和使用的结果。 和人类 服务疼痛管理机构间工作组已确定“自我 作为改善慢性疼痛的最佳实践之一，干预措施并不能成为改善慢性疼痛的最佳方法。 由于我们目前对癌症门诊患者疼痛自我管理的理解存在严重差距而设计 特别是他们的阿片类药物自我管理最近的系统评价表明大多数癌症疼痛。 干预措施（基于知识翻译，主要或专门针对白人患者进行） 提高知识，但很大程度上不会改善对患者重要的结果，例如日常疼痛、功能或 这强调需要继续寻找其他干预措施的目标。 为期 6 个月的前瞻性队列研究将产生关于纵向疼痛、阿片类药物自我治疗的新知识 癌症门诊患者在日常疼痛、疼痛的背景下的管理轨迹和相关结果 耀斑、关键临床调节因素和协变量 总共 400 名癌症门诊患者（50% 为非裔美国人；50%）。 将从三个城市肿瘤中心招募服用长效（LA）阿片类药物的女性）。 将使用药物事件监测实时捕获纵向阿片类药物自我管理模式 系统 (MEMS®) 将使用“按需”收集每日背景疼痛、疼痛发作和阿片类药物的使用情况。 待评估的自我报告追踪器 (SRT®) 是疼痛程度的变化， 功能、睡眠和健康相关的生活质量包括计划外住院治疗。 该研究将提供严格、全面的数据。 一组社会人口统计学和临床​​协变量，以及进一步研究疼痛自我的关键调节因素 管理最佳实践可以作为基础，包括改善种族差异的目标。 研究可以对癌症疼痛治疗科学产生持续影响。